GlassScriptPhysician profile
Sara Keihany
NPI 1912499203
$1,149.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $669 · 2022: $481.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $317.57 | 2021-2022 | |
| Glaxosmithkline, LLC. | $149.06 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.94 | 2021-2022 | |
| Therapeuticsmd, INC. | $89.93 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $87.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $83.38 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $71.06 | 2021-2022 | |
| Eisai INC. | $43.50 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.48 | 2021-2022 | |
| Scynexis, INC. | $35.86 | 2021-2022 | |
| Myovant Sciences INC. | $32.51 | 2021-2022 | |
| Davol INC. | $28.25 | 2022 | |
| Baudax Bio INC. | $17.91 | 2021 | |
| Evofem Biosciences, INC. | $15.84 | 2021 | |
| Ethicon US, LLC | $14.72 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Keihany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.